Background: We investigated the efficacy and safety of tandem high-dose methotrexate (HD-MTX) induction followed by high-dose busulfan/thiotepa (HD-BuTT) with autologous peripheral blood stem-cell transplantation (aPBSCT) and response-adapted whole-brain radiation therapy (WBRT) in patients with newly diagnosed primary central nervous system lymphoma.
centre B cells [2, 3] . Whole-brain radiation therapy (WBRT) with a median survival of 12-18 months was regarded standard treatment [4] since DeAngelis introduced combined modality treatment (CMT) [5] increasing median survival to 37-60 months [6] [7] [8] . The most effective component of this treatment is high-dose methotrexate (HD-MTX), obviating the need for intrathecal MTX, but its dosage, the optimal number of treatment cycles and cycle length is yet undetermined [9] . The value of combined or sequential addition of other cytostatic drugs and the role of WBRT in achieving and maintaining a response is still under investigation.
WBRT fuels an ongoing controversy [10] as it seems to grossly contribute to neurotoxicity affecting up to 90% of the elderly patients [11] . Deferring WBRT until relapse to avoid neurotoxicity was studied and results approached those of combined modality treatment [12, 13] . In further reducing neurotoxicity, HD-MTX monotherapy was investigated and showed response rates up to 100% and estimated median survival of 30 months with low acute and long-term toxicity [14, 15] . But, as recently shown, HD-MTX monotherapy could also compromise results with a low 35% response rate and short relapse-free survival of 13.7 months even for patients in CR after treatment [16] , calling for additional measures to increase response and prevent relapses. Deducted from the excellent treatment results in systemic lymphomas such measures could be high-dose chemotherapy (HDC) and autologous transplantation, CNS tailored with blood-brain barrierpenetrating lipophilic drugs, e.g. busulfan and thiotepa. Few data only are published for high-dose therapy in PCNSL showing response rates of 100% [17] , 82% [18] and median overall survival (OS) up to 91 months [19] in a poor prognosis group of patients.
The herein presented multicenter OSHO-53 study (Ostdeutsche Studiengruppe Hämatologie und Onkologie) investigates a time-and dose-intense treatment regimen in patients with PCNSL. The study was designed to obtain a high CR rate and long-term remission by combining two courses of induction HD-MTX with consolidating HD-BuTT, but to avoid the neurotoxic WBRT for patients in CR after chemotherapy.
patients and methods

eligibility criteria and baseline evaluation
Inclusion criteria were histologically confirmed newly diagnosed nonHodgkin's lymphoma of the CNS, biological age 18-65 years, minimum Karnofsky score 50% (CNS any), exclusion of infection with hepatitis B virus, hepatitis C virus (HCV), human immunodeficiency virus, previous malignant disease and absence of severe comorbidity; patients with heart, lung, kidney or liver disease had to be excluded. Systemic lymphoma had to be excluded by bone marrow examination, thoracic computed tomography scan and abdominal ultrasound as minimal requirements. Positron emission tomography scans were not done. The following ranges for laboratory parameters were required: creatinine £150% of the upper normal value, creatinine clearance at least 70 ml/min, bilirubin, alanine aminotransferase and aspartate aminotransferase £200% of the upper normal value, haemoglobin level ‡90 g/l, platelet count ‡100 000/ll and leucocyte count ‡1500/ll. Inclusion and exclusion criteria were assessed by the responsible physician at the site of treatment. All decisions regarding the treatment were left to the discretion of the treating physician and followed guidelines of the participating centre. The protocol was reviewed and approved by the local institutional review boards. Prior enrolment voluntary, informed and written consent was obtained from all patients. original article
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An extended screening for somatic toxicity was performed yearly. Carbamazepin was recommended as anticonvulsant therapy throughout the treatment since October 2001 as some patients had experienced hepatic toxicity while on phenytoin.
response evaluation
End points of this multicenter phase II study were the rates of remission achieved at each treatment step, survival and toxicity. CR required the complete resolution of contrast enhancing lesions, PR a reduction by more than 50% and progressive disease anenlargement of contrast-enhancing lesions by more than 25%. All other situations were considered no change (NC). Toxicity was graded according to World Health Organisation criteria. All survival data were calculated from the day of first treatment. Any progression, relapse or death due to lymphoma or therapy were considered events in the event-free survival analysis. Patients who died of causes unrelated to PCNSL or its treatment were censored at the date of death ( Table 2 , second patient). All events within 30 days of administration of chemotherapy were regarded as treatment related regardless of the causality and at any time if causality to treatment was assumed. Analysis was performed on the principle of intention-to-treat, if not otherwise stated. In November 2004, the study was closed as both the planned number of enrolled patients and the prespecified stopping rule for treatment-related deaths were met. Follow-up extends through July 2005.
results patients characteristic
Twenty-three patients, 11 women and 12 men, were enrolled in this study from August 1999 to November 2004 at five participating centres, three university hospitals and two large academic teaching hospitals. Median age was 55 years (range 18-69), median Karnofsky performance score 70% (range 30-100) and median 'Ferreri' score 3 (range 0-5) [20] . No patient had intraocular lymphoma or evidence of systemic lymphoma at the time of enrolment. All patients underwent thoracoabdominal CT scanning for initial staging. Twenty-two patients had histologically confirmed DLBCL, one patient an unclassified T-cell lymphoma. Two patients achieved CR and five patients PR after neurosurgical intervention. The time to diagnosis varied from 0 to 721 days with a median of 45 days. In one case, PCNSL was detected incidentally by MRI carried out for other reasons. Details are given in Tables 1 and 2 . + cells/kg BW (range 2-9) were given with leucocyte recovery >1000/ll on day 8 (median, range 7-12) and thrombocyte recovery of >50,000/ll on day 11 (median, range [8] [9] [10] [11] [12] [13] [14] [15] . Two patients in PR and one patient with progressive disease after HD-BuTT received response-adapted WBRT leading to an additional two complete and one partial responses, respectively. A total of nine patients were irradiated (NC after HD-MTX = 4, due to MTX toxicity = 2, post-HD-BuTT = 3) (See Figure 1 for flow of patients and Table 3 ). Treatmentassociated toxicity was seen in 16 patients (Table 2) but changed the treatment course in three patients only (Figure 1 ). Three irradiated patients died of neurotoxicity at 6, 10 and 27 months.
response rates and survival data
Overall CR/PR rates were 70%/13% (n = 23) herein included the patients with early WBRT carried out because of MTX-related toxicity (n = 2) or because of NC or PD after HDMTX (n = 4) and patients with WBRT after HDC (n = 3). At a median follow-up of 15 months, the median OS and EFS were 20 and 17 months for all patients, for patients treated with HD-BuTT 'not reached' and 27 months, respectively. Two-year OS and EFS were 48% and 45% for all patients, 61% and 48% for the HD-BuTT group, respectively (Figure 2 ). (Ferreri et al. JCO 2003) ; DP, diagnostic procedure (operation/biopsy)-reported is the best result after the respective intervention or treatment, followed by a description of toxicity (tox); na, not available; CR, complete remission; PR, partial remission; NC, no change; PD, progressive disease; MTX, methotrexate; HD-BuTT, high-dose busulfan/thiotepa; extrapyr., extrapyramidal; WBRT, whole-brain radiation therapy; ÿ, not applicable; Neuro-Tox, clinically relevant neurotoxicity; Relapse/progress, time of relapse or progression after initial treatment, salvage therapy and response to salvage therapy; LFU, length/status last follow-up; CoD, cause of death; hep, hepatic; hem, haematologic; RPA, patient resumed previous daily/professional activities; muc, mucositis; R-CHOP, rituximab-combination chemotherapy with cyclophosphamide, doxorubicin, vincristine and prednisone; PD, progressive disease; syst, systemic; DHAP, combination chemotherapy with dexamethasone, high-dose cytosinarabinosid and cisplatin; HDC, high-dose chemotherapy; infect, infection; vent, ventilation (invasive and noninvasive); DVT, deep vein thrombosis; SU, remission status unknown; PE, pulmonary embolism; RHF, right heart failure; MOF, multi organ failure including ventilation; HD-AraC, high-dose cytosinarabinosid.
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Survival was strongly determined by toxicity, response to HD-MTX and treatment with HD-BuTT. Early toxic deaths and fatal neurotoxicity in irradiated patients accounted for the disappointing short-term results while encouraging long-term results were determined by responders to HD-BuTT. The latter group showed no clinical signs of neurotoxicity and resumed their previous daily or professional activities. There were three systemic relapses 6, 9 and 49 months after start of therapy, two successfully treated with rituximab-combination chemotherapy with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) polychemotherapy, one patient with testicular relapse receiving ongoing treatment with rituximab-CHOP (staging testicular ultrasound was negative).
Upon univariate analysis, we found no correlation of LDH, involvement of deep brain structures, multilocular manifestation or Karnofsky performance score with outcome. There were no significant differences between patients >60 years and younger patients (P = 0.42, log-rank test). Patients not receiving HD-BuTT had a dismal prognosis with no patient alive beyond 19 months on Kaplan-Meier analysis of OS (Figure 2) .
discussion
This multicenter phase II trial investigated the efficacy and safety of tandem HD-MTX induction followed by HD-BuTT and autologous peripheral stem-cell transplantation as primary treatment of PCNSL. On the basis of the promising pilot data of HD-MTX therapy [14, 21, 22] and pharmacokinetic considerations [23] , we chose a time-intense tandem 8 g/m 2 HD-MTX as induction therapy. We expected a response rate >80% and therefore most patients to undergo HD-MTX followed by HD-BuTT. HD-BuTT was chosen because of encouraging pilot data [24] with busulfan [25] and thiotepa [26] achieving high cerebrospinal fluid levels.
Unexpectedly, in our group the CR rate after HD-MTX induction was 17% only with two toxicity-related drop outs and one treatment-related death. This differs from the 65% CR rate in a single-institution study [14] and the 52% CR rate [15] in a multicenter setting, while a German multicenter study [16] achieved a 30% CR rate only with a similar regimen. Differences in the number of MTX cycles given, namely two cycles in this study, a median three cycles in the NOA-3 study [16] and a median six cycles to best response in the NABTT-trial [15] might account for differing response rates and underline the problems with cross-study comparisons (NOA, Neuroonkologische Arbeitsgemeinschaft, Germany; NABTT, New Approaches to Brain Tumor Therapy, USA). Sample size bias or chance differences, however, cannot be ruled out. Although there were no obvious differences in eligibility criteria, especially renal function, MTX-infusion or leucovorin rescue [16] we cannot rule out differences in MTX metabolism. First, assessment of renal function is notoriously difficult and subject to great variability [27] , but important, as MTXclearance and MTX-area under the curve correlate to rates of response and toxicity [28] . Secondly, drug interactions could increase the level of active MTX and its metabolites not determined by standard assays as shown, e.g. for pantozole [29] . Furthermore, differences in MTX-metabolising methionin synthase could account for differing toxicity [30] and outcome [31] .
The treatment-related mortality (TRM) in this study was higher than that reported for HDC of entities other than PCNSL, but usually a Karnofsky index below 70% is an exclusion criterion in such protocols [32, 33] . Even after conventional chemotherapy, patients with PCNSL suffer from higher TRM than patients with peripheral lymphoma. Therefore, the herein reported 13% treatment-related deaths were in line with the previously reported 5%-29% TRM rates [6, 9, 12, 34, 35] . One reason for the high TRM might be the high grade of immobilisation of patients with PCNSL. In particular, the occurrence of pulmonary embolism in two of 23 patients and one fatal pneumonia in this study cohort might have resulted from this feature. Pels et al. [12] described three of 65 patients experiencing deep venous thrombosis, Poortmans et al. [6] thromboembolic complications in four of 52 and Calderoni and Aebi [34] one treatment-related death caused by pulmonary embolism in 14 patients. In this study eight of nine irradiated patients developed clinically relevant neurotoxicity, leading to death in three patients. Resource intense, individualised neuropsychological testing was not performed in this phase II study because we did not expect to generate meaningful data. One patient received only 31 Gy and showed no neurotoxicity at a follow-up of 11 months. The NOA-03 investigators report a 58% neurotoxicity rate in irradiated patients versus 10% in nonirradiated patients [36] , confirming our assumption that WBRT should be avoided in first-line therapy of PCNSL and postponed until relapse. This approach of deferred radiotherapy does not compromise the efficacy of WBRT as recently shown [13, 36] .
HD-BuTT was a very effective component of our treatment plan that increased CR rates from 17% to 48% (n = 23) and was able to induce a CR in a patient with progressive disease. The CR rate is 69% for the 16 patients treated with HD-BuTT. There were no signs of clinical neurotoxicity after HD-BuTT and therefore five out of seven nonirradiated patients alive at the time of this analysis returned to their previous daily or professional activities. Furthermore, duration of treatment is very short, that being by itself an important aspect of patients' quality of life. Another advantage of this treatment strategy is 
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that it does not require a maintenance therapy [15, 16] and therefore is finished after 2-3 months only. The 2-year OS rates of our study were 48% for all and 61% for HD-BuTT patients at a median follow-up of 15 months. For the group of patients who underwent HD-BuTT, median OS was not reached yet. Other groups investigating HDC have reported a median OS of 24 months [17] and 91 months [19] , the latter being the longest OS reported yet for PCNSL to our knowledge. Illerhaus et al. [37] recently reported an OS of 64% for all patients, and 81% for the patients who received the planned HD-MTX/HD-AraC/ thiotepa induction followed by HD-camustine-thiotepa/ autologous peripheral blood stem-cell transplantation and consolidating WBRT, at a median follow-up of 37 months.
In contrast to the general notion that age is a strong prognostic factor in PCNSL [7, 12, 20] , we found no outcome differences between patients >60 years and younger patients (P = 0.42, log-rank test), but this might be a chance finding due to the small number of patients treated.
We conclude that primary high-dose therapy for PCNSL is a promising approach with good response rates, without severe neurotoxicity when WBRT avoided, and safely applicable even in the elderly. This and the short duration of therapy have substantially contributed to the patients' quality of life. But it has to be pointed out that tandem induction therapy with HD-MTX alone seems to be insufficient and should be improved. Future trials investigating high-dose chemotherapy should include a more powerful induction therapy, but should avoid radiotherapy of the brain [38] .
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